LL5 Siphoviridae Bacteriophage.

LL5 is a lytic phage against defined Escherichia coli strains, and lysing those cells frees substrate and surface in the intestinal niche. Co dosed probiotic strains are not phage hosts and are the ones able to occupy it.

Phage adsorption depends on receptors present on the coliform target and absent from lactobacilli, so the delivered strain survives co formulation. The result is less competition for the same nutrients.

A lytic phage only replicates where its bacterial host is replicating, so the size and activity of the target population sets how much a phage preparation can do. Inulin is fermented by bifidobacteria and shifts which taxa are expanding in the colon. Pairing the two is a formulation logic about substrate and host density, not a tested combination. Read it as mechanistic.

Short-chain fructans are fermented in the proximal colon and raise the metabolic activity of saccharolytic bacteria. Phage propagation depends on metabolically active hosts, so substrate supply is part of the context in which a phage preparation acts. No combination trial supports the pairing. The basis is mechanistic reasoning about the environment both act in.

Galactooligosaccharides are selectively fermented by bifidobacteria and lactobacilli and are common companions to live-organism formulas. A phage preparation targets a narrow bacterial host range and leaves non-host taxa untouched, so the two act on different parts of the community. The pairing is formulation logic rather than a measured interaction.

Resistant starch reaches the colon intact and feeds fermenting bacteria that produce short-chain fatty acids. Phage activity is host-specific and does not depend on the starch itself. Any combined effect would run through the bacterial community both touch. This is mechanistic, not clinical.

Siphoviridae phages infect a defined bacterial host range and do not lyse taxa outside it. That specificity is the reason phage preparations are formulated next to live bifidobacteria rather than against them. Whether a given phage stock spares a given commercial strain is a manufacturing question answered by host-range testing, not something a shopper can assume. Read the pairing as design intent with a testable basis.

Host range is the defining property of a phage preparation, and a strain outside that range is not a target. Formulas that place a phage blend beside Bifidobacterium lactis rely on that separation. Confirmation for any specific pair comes from host-range panels run by the manufacturer. No human combination data was located.

Lactobacillus strains carry their own phage susceptibility profiles, which is why dairy fermentation has tracked phage-host pairs for decades. A phage preparation intended for a Gram-negative or a specific Gram-positive host does not act on an unrelated Lactobacillus. The pairing is a formulation decision resting on host-range data rather than on a clinical trial.

Saccharomyces boulardii is a yeast, and bacteriophages have no capacity to infect eukaryotic cells. The two occupy completely separate target classes in the same product. That is settled microbiology and needs no trial. It says nothing about whether either produces an effect on its own.

Butyrate is the main energy substrate of colonocytes and is produced by a subset of anaerobes. A phage that narrows one bacterial population can shift which taxa dominate fermentation, which is the route by which the two could touch. Direction and size of any such shift were not measured in the sources located. This is a mechanistic connection, not an outcome.

Phage capsids and their genomes lose infectivity at gastric pH, which is why oral phage preparations are buffered, enteric coated or taken with food. Sodium bicarbonate raises gastric pH transiently and is a standard buffering companion in phage delivery work. The practice is about survival of the particle in transit rather than any added biological effect. It is formulation practice with a clear physical basis.

A phage particle is a protein shell around nucleic acid, and concentrated exogenous proteases act on protein. Co-dosing a high-activity protease blend with a live phage preparation is a plausible route to loss of infectious titre before the particle reaches the colon. No study measuring this pairing was located. Flagging it as a formulation caution rather than a measured effect.

Psyllium forms a viscous gel that slows gastric emptying and changes how material is presented to the colon. Any bulk-forming fibre therefore changes the transit window a live preparation experiences. Whether that helps or hinders phage delivery has not been measured. Read it as a formulation variable to consider.